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ABSTRACT 
 
Stem cells can be classified as embryonic stem (ES) cells or adult stem cells considering their origin. If plasticity is considered, 
stem cells can be classified as totipotent, when stem cells retain the ability to give rise to an entire new organism. When stem cells lose 
this capacity, cells are named pluripotent stem cells, which can give rise to almost all mature cell types that compound an organism. 
Totipotent and pluripotent stem cells can be obtained from developing early-stage embryos. Multipotent is the group of adult stem cells 
with restricted plasticity. These cells can differentiate into a defined cell type related with a specific organ or tissue. ES cells can be 
propagated in vitro under undifferentiated system or with a series of protocols to induce cell differentiation. On the other hand, multipotent 
adult stem cells cannot be maintained in vitro in an undifferentiated form, except for a special class of adherent adult stem cells named 
mesenchimal stem cells, which can be expanded in vitro conserving their undifferentiated characteristics. Considering the ability to gen-
erate teratomas, ES cells were not used in experimental in vivo cell transplant. On the other hand, several experimental adult stem cells 
transplants have been performed with controversial results. 
Keywords: Stem cell, embryonic stem cell, adult stem cell, cell differentiation, cell therapy. 
 
RESUMO 
 
Considerando a origem de obtenção, as células-tronco podem ser classificadas como células-tronco embrionárias (ES) ou como 
células-tronco adultas. Mas, se a plasticidade for considerada, as células-tronco podem ser classificadas como células totipotentes, 
quando as células-tronco preservam a capacidade de dar origem a um novo indivíduo completo. Quando as células-tronco perdem esta 
capacidade, passam a ser classificadas como células-tronco pluripotentes, que podem dar origem a praticamente todos os tipos celula-
res maduros que compõem um organismo. Células-tronco totipotentes e pluripotentes podem ser obtidas de estágios embrionários 
iniciais. 
O grupo de células-tronco que apresenta plasticidade restrita é denominado de multipotente. Estas células podem se diferenciar 
em determinado tipo celular comprometido com um órgão ou tecido específico. Células ES podem ser expandidas in vitro, mantendo sua 
forma indiferenciada, ou podem ser submetidas a uma série de protocolos, que irão induzir diferenciação in vitro. Por outro lado, as 
células-tronco adultas multipotentes não podem ser mantidas in vitro na forma indiferenciada, exceto uma subpopulação de células-
tronco adultas aderentes, denominadas células-tronco mesenquimais, que podem ser mantidas in vitro na forma indiferenciada. Consi-
derando a capacidade de gerar teratomas, as células ES não foram utilizadas para transplante celular experimental in vivo. Além disso, 
várias cirurgias de transplantes experimentais com células-tronco adultas têm sido realizadas, porém apresentando resultados contro-
versos. 
Unitermos: Célula-tronco, célula-tronco embriônica, célula-tronco adulta, diferenciação celular, terapia celular. 
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STEM CELLS CLASSIFICATION 
 
As mentioned by Boheler et al. (1) or reviewed by 
Wobus & Boehler (2), stem cells are those cells that self-
renew and retain the capacity for either embryonic devel-
opment or tissue regeneration. Stem cells can be classified 
using different characteristics. If origin is considered, stem 
cells are classified as embryonic or adult stem cells. Em-
bryonic stem (ES) cells can be isolated by early-stage em-
bryo. Stem cells obtained from adult tissues are named 
adult stem cells. 
On the other hand, if plasticity is considered, stem 
cells can be classified as totipotent, pluripotent or multipo-
tent stem cells. Undifferentiated cells with the capacity to 
generate an entire organism can be encountered exclusively 
on early stages of fertilized eggs or considering the devel-
oping embryo from zygote to 8-cell stage embryos (Figure 
1). These undifferentiated cells can give rise to all required 
embryonic and extraembryonic tissues to generate a new 
organism and this is the reason to be classified as totipo-
tent. Cells obtained from the inner cell mass (ICM) of pre-
implantation blastocyst are no longer totipotent. Loss of 
totipotency is therefore related to the developmental fate of 
the organism. ES cells obtained from the ICM of blastocyst 
lose the ability to generate an entire new organism because 
they lose the capacity to generate extraembryonic tissues. 
However, these pluripotent cells retain the ability, in de-
fined conditions, to generate all cell types derived from the 
three germ layers: ectoderm (epidermal tissues and nerves), 
mesoderm (muscle, bone and blood) and endoderm (liver, 
pancreas, gastrointestinal tract, lungs), including fetal and 
adult cells. Although these cells alone do not develop into a 
viable fetus or adult animal, they retain an undifferentiated 
form and the capability to originate almost all different cell 
types which compose an entire organism. Lastly, cells with 
reduced plasticity, with the ability to generate some differ-
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ent cell types in special conditions are considered multipo-
tent. 
These two different systems of stem cell classifica-
tion can be overlapped and it will be possible to classify 
stem cells, for example, as pluripotent ES cells obtained 
from a mouse blastocyst, or pluripotent stem cells obtained 
from an adult undifferentiated carcinoma, an adult or dif-
ferentiated tissue. Considering that issue, we will focus our 
discussion on pluripotent stem cells obtained from blasto-
cysts and multipotent adult stem cells obtained from differ-
ent adult tissues as described below. 
 
PLURIPOTENT STEM CELLS 
 
In 1975, Martin & Evans (3) obtained the first 
pluripotent cell line from murine teratocarcinomas. These 
cells are called embryonic carcinoma cells because they 
present similar characteristics to cells obtained from early-
stage embryos. 
Another group of pluripotent adult cells was isolated 
from spontaneous testis teratocarcinomas. These cells were 
exhaustively studied by Tam & Zhou (4), who encountered 
cells with the same characteristics on mouse epiblast em-
bryos. Then this group of pluripotent cells was named as 
primordial germinative cells. 
Later, pluripotent ES cells were isolated from the 
ICM of blastocyst-stage preimplantation mouse embryos 
(Figure 1) by Evans & Kaufman in 1981 (5) and independ-
ently by Martin (6). The plasticity of pluripotent ES cells 
should be addressed when teratocarcinomas are formed 
after the injection of undifferentiated ES cells on recipient 
animals (7), but not viable embryos. Furthermore, when ES 
cells are transferred to a developing embryo, they can be 
reintegrated into ICM and give rise to all mature cell types, 
including germinative cells (8). It is important to note that 
this phenomenon can occur also when ES cells are geneti-
cally manipulated, for example. In this vein, a series of 
knockout animal models were established using this meth-
odology. In 1998, Thomson et al. (9) were able to isolate 
ES cells from in vitro fertilized human embryos (blasto-
cysts). Furthermore, Wobus (10) described ES cells as a 
group of stem cells with an unlimited capability of propa-
gation in vitro under undifferentiated forms, besides the 
ability to differentiate into differentiated somatic cells. In 
addition, ES cells can also be characterized by high alka-
line phosphatase activity; expression of embryonic specific 
markers as SSEA-1; small cytoplasm; high telomerase 
activity, self-division modulated by interleucin-6 (IL-6) 
family (7,11,12). 
Several other pluripotent ES cell lines have been es-
tablished from rodents (13,14), rabbits (15), pigs (16), 
primates (17) and a considerable number of human cell 
lines has been established (18-22). These cell lines have 
been obtained applying almost the same protocol, using 
blastocysts to isolate ES cells from the ICM. The huge 
plasticity of pluripotent ES cells was demonstrated in vivo 
and in vitro. When injected into blastocysts or under the 
kidney capsule, these cell lines produce cells from all three 
germ layers representing endoderm, ectoderm and meso-
derm. Otherwise, pluripotent characteristic or plasticity of 
ES cells can also be addressed in vitro. Comparing the 
three different pluripotent stem cells, ES cells obtained 
from preimplantation blastocyst present the best way to 
perform in vitro differentiation experiments, considering 
ES cells ability to propagate and maintain their plasticity in 
culture systems (7). 
 
 
Figure 1 – Early Embryo Development 
Spermatozoid fusion with an oocyte produces a unique cell embryo named zygote. With adequate conditions, in vivo or in 
vitro zygote divides and produce a 2-cell embryo. In a subsequent stage, both split and give rise to 4-cell embryo. Subse-
quently, 8-, 16-, 32-cell will be generated by blastomers divisions. Morula is the stage where embryo is formed by a non-
measured compact cell mass. The next step will form the pre-implantational blastocyst. Totipotent embryonic stem (ES) 
cells can be obtained by collecting blastomers from 2- to 8-cell embryos. Totipotent ES cells can give rise to an entire or-
ganism. Pluripotent stem cell lines can be established collecting cells from the inner cell mass of a blastocyst. Pluripotent 
stem cells have no ability to generate extra-embryonary structures, considering that it cannot form a new organism. How-
ever, pluripotent stem cells can generate all cell types from the three germ layers: ectoderm, mesoderm, endoderm. 
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IN VITRO PLURIPOTENT ES CELLS 
 
ES cells can be expanded in vitro in two different 
conditions. Applying specific cell culture conditions it is 
possible to avoid the natural characteristic of ES cells to 
divide and differentiate. Co-cultivating ES cells with inac-
tivated embryonic fibroblast cell cultures which secrets 
inhibitory factors combined with a specific cell culture 
media supplemented with leukemia inhibitor factor (LIF) 
(23,24), ES cells can be infinitively propagated in an undif-
ferentiated state. IL-6 and oncostatin have been mentioned 
as factors that can negatively interfere with ES cell differ-
entiation. Thus, ES cells can be propagated in vitro main-
taining their undifferentiated state. Alternatively, ES cells 
could be submitted to different cell culture protocols in 
order to guide ES cells in vitro differentiation. As reviewed 
by Wobus & Boheler in 2005 (2), three different protocols 
were described to induce in vitro formation of ES cell ag-
gregates named embryoid bodies (EB). EB can be culti-
vated in a series of conditions to produce different mature 
cell types in culture. In order to obtain EB, Wiles & Keller 
(25) described a method by cultivating ES cells with 
methyl cellulose. Or applying the method named mass 
culture ES cells were cultivated under high density and in 
the presence of specific factors EB can also be obtained 
(26). Our group and most research groups adopted the 
hanging drop technique established by Wobus et al. (27). 
With this technique, a number of undifferentiated ES cells 
were cultivated in a hanging drop to achieve through the 
formation of cell aggregates the three dimensional structure 
called EB. EB were maintained under specific conditions to 
differentiate into different cell types. The kinetic of in vitro 
EB development is similar to in vivo embryo development. 
Therefore, at the beginning of culture it is possible to ob-
serve mesoderm and ectoderm precursor cells, while endo-
derm-derived cells can be detected at least 10 days after EB 
culture. 
It is important to note that today only mixed cell 
type cultures should be obtained from ES cell cultures. 
Different protocols have been described in order to enrich a 
mix cell culture in a specific cell type. However, no proto-
col can guide ES cells in vitro differentiation to a unique 
specific cell type. Clusters of cardiomyocytes, neurons, 
smooth muscle cells, skeletal muscle cells and epithelial 
cells represent the majority of mature cells obtained in ES 
cell cultures after differentiation induce protocol. 
 
MULTIPOTENT ADULT STEM CELLS 
 
Initially, multipotent adult stem cells were known as 
stem cells committed with a specific tissue or organ confer-
ring a limited plasticity to them. Later, studies demon-
strated that adult stem cells have a wide plasticity, but are 
not completely understood (28-30). 
Nowadays, adult stem cells can be classified as mul-
tipotent, considering their reduced plasticity. Adult stem 
cells are cells obtained from adult or differentiated tissues. 
The main category of adult stem cells is the hematopoietic 
stem cells (HSC) encountered in the bone marrow (BM). 
HSC is currently the best characterized multipotent adult or 
somatic stem cell population and was prospectively iso-
lated from mouse BM about 15 years ago (31). Interest-
ingly, there are approximately 5x 1011 cells on BM but only 
1% of these cells are progenitor cells involved with hema-
topoietic system and 0.001% are stem cells (32). On 50th 
of last century, HSC were known, but could not be isolated 
considering that no specific markers were described to this 
cell type neither monoclonal antibodies technology was 
available. However, in cell culture systems where a cell 
suspension obtained from BM was cultivated in an in vitro 
system called “limit dilution”, it was possible to have evi-
dence of the existence and the potentiality of HSC. In this 
system, a preparation of BM cell suspension was plated 
with a density of one cell per well in a 96 well plate. In this 
way, only one cell per well was cultivated in a defined 
condition and it develops and gives rise to a colony com-
posed by different blood cell types. This experiment dem-
onstrated that only one cell could give rise to a series of 
different mature blood cells, such as lymphocyte cell line 
or granulocyte-macrophage cells, for example. In this vein, 
it was possible to detect all mature blood cells in other 
wells. This clear-cut procedure demonstrated that a mix of 
stem cells reside at the BM. The most undifferentiated one 
was called HSC and these cells give rise to all mature 
blood cell lines. In addition, other committed stem cells 
were detected. For example, it was possible to show the 
existence of a stem cell committed specifically with granu-
locyte-macrophage (GM) cell lines and other stem cells 
committed with lymphocyte cell lines. These data are col-
lected in a “pyramid”-like cell differentiation system pro-
posed to the hematopoietic cells, where the top of the 
pyramid is occupied by the HSC, which is the most undif-
ferentiated cell from blood cell lineages. Downstream, 
other stages of more differentiated stem cells from HSC 
were detected. Later the blood cell-lineage-committed stem 
cells and the different stages of adult or differentiated 
blood cell lines were encountered, as pro-B, pre-B and B 
lymphocytes, for example. At pyramid base resides mature 
blood cell lines. 
Recently, a new cell division mechanism was dem-
onstrated to adult stem cells in vitro by Sherley (33). Stem 
cells apparently divide into a special process named asym-
metric division, represented in Figure 2. During the cell 
division process, the mother cell divides and produces two 
daughter cells. One of the daughter cells is equal to the 
undifferentiated mother stem cell and the other daughter 
cell is different from the mother cell. This other cell under-
goes a cell differentiation process and will be committed 
with a group of lineage cells. In this vein, stem cell replica-
tion occasionally produces two different daughter cells, an 
undifferentiated one equal to the mother cell, and a second 
one different from the mother-cell which starts to differen-
tiate and gradually loses its stem cell potentiality, because 
it becomes specialized to perform functions related to a 
specific mature cell type. This hypothesis tries to explain 
the self-renewal of stem cells in adult tissues or adult or-
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ganism, besides the stem cell ability to differentiate and 
give rise to different cell types. 
Another multipotent stem cell type has been isolated 
from BM, submitting BM cell suspension to an adherent 
cell culture system. In vivo and in vitro, most hematopoi-
etic cells encountered on BM cell suspension were not 
adherent cells, except monocyte-macrophage cells. When 
BM cell suspension was submitted to adherent cell culture 
systems, most cells became on the supernatant phase and 
macrophage, fibroblast, endothelial cells and other adherent 
cell types became attached to the culture flask. The hema-
topoietic non-adherent cells were discarded with the cell 
culture medium some days latter. A mix of adherent cell 
types was obtained with this system. One to 2 weeks latter, 
the majority of differentiated cells, such as macrophage, 
fibroblast, endothelial cells and other mature cell types 
died. Some undifferentiated fibroblast-like adherent cells 
persist for several weeks in this system and these are 
named mesenchimal stem cells (MSC). MSC is a multipo-
tent adherent stem cell obtained from BM aspirates and 
was firstly obtained from mouse BM (30,34-36). Only 
recently specific cell markers for the prospective isolation 
were described (37). 
In parallel, other adult stem cell populations have 
been described in differentiated tissues. Furthermore, BM 
adult stem cells have been described on umbilical cord, 
blood, brain, spinal cord, skeletal muscle, epidermal tis-
sues, and pancreas (7). Stem cells encountered on umbilical 
cord presents similar characteristics to BM stem cells, but 
with higher plasticity (38,39). These other adult stem cells 
were known to be committed with tissue-specific repair. 
Despite the lack or controversial identification of cell 
markers in this group of adult committed stem cell popula-
tions, the specific mechanism of action of these cells is also 
unclear. Tissue- or organ-specific committed stem cells 
have been described as tissue-resident stem cells from 
peripheral nervous system (40,41); and from central nerv-
ous system (42-44). Furthermore, there is evidence of the 
existence of other organ-specific committed stem cells 
encountered on skeletal muscle (45), or epidermal stem 
cells located on the boundary of hair follicle (46); on gut, 
where committed stem cells reside near the bottom of the 
intestinal crypts (47,48). Yet, muscle-committed stem cells 
have been described (49-52) and brain-resident stem cells 
too (53,54). Moreover, other groups demonstrated evidence 
of the presence of liver stem cells (55,56) and pancreas-
resident stem cells were described by Bonner-Weir & 
Sharma (57) and by Murtaugh & Melton in 2003 (58). In 
fact, the controversial existence and whether tissue regen-
eration is mediated by adult stem cells or not, must be 
elucidated. Forbes et al. (55) proposed that different tissue 
regenerative populations may function in response to tissue 
injury as opposed to tissue homeostasis. As reviewed by 
Wagers & Weissman (59), adult stem cell populations that 
appear to normally give rise to tissues of multiple germ 
layers have recently been found by culture methods from 
the skin (60), BM (61,62), muscle (62-64) or brain (62). 
Complementary experiments will be necessary to under-
stand tissue regeneration in parallel with adult stem cell 
plasticity. 
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Figure 2 – Asymmetric Division 
Adult stem cells present a special self-renewal process named asymmetric division in vitro observed. Frequently a single 
stem cell divides and generates two daughters-cells equal to the undifferentiated mother cell. Occasionally, stem cells per-
form a special division process, where mother cell produces two distinct cells. One cell will be equal to the undifferentiated 
mother cell. The second daughter cell will differentiate and compromise with a specific cell type differentiation process. In 
asymmetric division, stem cells divide and generate new undifferentiated cells for self-renewal. In parallel new differenti-
ated committed stem cells will be generated to give rise to new cells of different tissues and organs. 
 
IN VITRO ADULT STEM CELL 
 
Differently from ES cells, there is no established 
protocol to expand undifferentiated adult stem cells in 
vitro, except to the MSC. When BM aspirate, for example, 
is submitted to special cell culture system, stem cells 
propagate, but give rise to differentiated cells. In fact, adult 
stem cells (again, except MSC) cannot be cultivated to 
propagate undifferentiated stem cells. However, it is ac-
ceptable that researchers have not understood exactly in 
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which in vitro systems adult stem cells must be cultivated 
to be propagated as undifferentiated stem cells. It means 
that nowadays, only the conditions to propagate MSC were 
described. MSC can be obtained from BM too. To isolate 
MSC, BM aspirate must be centrifuged in a Ficoll gradient 
to isolate peripheral blood mononuclear cells (PBMC). 
PBMC fraction must be cultivated in an adherent system. 
After 2 days, the non-adherent cells are discarded with the 
medium change. A mixture of adherent cells becomes at-
tached to the culture flask and it is possible to encounter 
fibroblasts, endothelial cells, macrophages, nerve cells and 
MSC. In appropriate conditions, MSC will divide maintain-
ing the undifferentiated state for long periods of culture. In 
the meantime, mature cells die and detach from culture 
flask. Then, in subsequently media changing, cultures are 
enriched in MSC almost to the totality. In this vein, consid-
ering adult stem cells, only MSC can be propagated in vitro 
under the undifferentiated state. Consequently, several 
analyses have been performed with this group of adult stem 
cells to characterize it. Thus, Wagner & Ho (65) define by 
flow cytometry a panel of surface markers that must be 
expressed on MSC membrane and at the same time there is 
another group of cell markers that could not be present on 
cell surface of MSC. Considering this panel, MSC must be 
CD105+, CD73+, CD90+ and CD45-, CD34-and CD11b/c. 
Despite the mentioned results, the existence of MSC is 
controversial. 
 
STEM CELL THERAPY AND PERSPECTIVES 
 
Considering the high plasticity of ES cells that can 
give rise to all cell types of an adult organism, undifferenti-
ated ES cells cannot be used for cell transplant to an indi-
vidual, because they will obligatorily induce formation of 
teratomas. As mentioned before, at the moment, there is no 
defined protocol to induce in vitro ES cell differentiation to 
obtain a pure cell type culture of cardiomyocytes cells or 
other. It is possible to enrich ES culture system in a specific 
cell type, but no guarantees can be offered to produce in 
vitro mature cells for in vivo cell transfer without a con-
tamination of undifferentiated ES cells and/or other mature 
cell types. This technical problem avoids application of ES 
cell for cell transplant. However, it is important to note that 
ES cell culture systems is the best in vitro system to study 
cell differentiation, and the development of research pro-
jects on in vitro ES cells are extremely important to help us 
understand several cell differentiation processes. In the 
future, with the acquisition of knowledge to manage ES 
cell in vitro differentiation, this option will certainly be 
available as a new alternative for cell or organ transplanta-
tion. 
On the other hand, transplant with adult stem cells 
has been a real practical alternative for human medicine 
and others since BM transplant has been performed on 50th 
of last century. In fact, the reconstitution of hematopoietic 
system in patients with hematopoietic neoplasias was per-
formed by BM aspirates obtained from healthy donors. 
Since the beginning, the exact mechanism of hematopoietic 
recipient system recovery is not well understood. However, 
with today’s technical development, it is possible to imag-
ine that HSC and other committed stem cells encountered 
on BM donors can help reconstitute the recipient hemato-
poietic system. Based on this procedure, many experimen-
tal therapeutic alternatives have been performed to treat a 
series of distinct diseases, as reviewed by Krause in 2002 
(66) and by Kraitchman et al., 2008 (67), for example. 
Successful experiments with BM transplant to hematopoi-
etic neoplasia patients, as well as the difficulties related to 
ES cell transplantation, inspire several groups to look for 
benefits conferred by unprocessed BM suspension cells or 
in vitro processed BM derived cells to almost all patholo-
gies. The success of this new therapeutic alternative can be 
observed with the high number of scientific articles report-
ing results obtained in 2008 using this approach to repair 
cartilage defects (68), heart failure (69,70), osteoarthritis 
(71) or neurological diseases (72). Nowadays, many groups 
around the world are trying to establish this therapeutic 
alternative to their patients, but little is known concerning 
the mechanism of action and the exact benefits for tissue 
injuries with stem cell transplantation. Most projects today 
are focused on bioengineering, concerning this topic to 
define the mechanism of action of in vivo stem cell and the 
reconstitution of tissue lesions. 
Despite these positive results, many groups detected 
no influence of stem cell transplant on tissue repair (73). In 
this vein, there were almost no detectable cells expressing 
Y chromosome in different organs of woman recipients of 
male HSC. On the other hand, it was possible to observe 
completely hepatic recovery in animals submitted to mouse 
experimental induced hepatic failure followed by HSC 
transplant. In addition to hepatic regeneration, stem cell 
donor markers were detected on recipient mature hepato-
cytes. These results corroborate the idea of transdifferentia-
tion, in which a stem cell differentiates to a specific cell 
type in response to microenvironmental signals and factors 
produced in the local injury. Later, other experiments dem-
onstrated that specific hepatocytes expressed at the same 
time recipient and donor cell markers. These results sug-
gested that donor HSC fuses with a recipient cell (such as a 
macrophage, for example). The same fusion phenomenon 
was observed with other tissues, such as cardiomyocytes or 
neurons (74). Nonetheless, other results demonstrated that 
these cells, which have donor and recipient markers simul-
taneously, expressed a normal number of chromosome 
suggesting that no fusion occurred. One more time, there is 
no consensus concerning the mechanism of interaction 
between transferred stem cells and recipient tissues. It is 
important to note that no negative or deleterious results 
were described. It is a fact that stem cells represent a new 
therapeutic alternative and it is important to continue inves-
tigating to establish an adequate treatment protocol for each 
pathology. Finally, election of three researchers investigat-
ing stem cell technology to receive the Nobel Prize of 
Medicine and Physiology in 2007 is the best demonstration 
of the real impact of stem cells around the world. 
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